Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses XFOR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named XFOR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Adam Craig | $179,629 | $0 | $0 | $6,410,958 | $114,479 | $0 | $139 | $6,705,205 |
| Executive Chairman | ||||||||
| John Volpone | 176,538 | 0 | 0 | 6,410,958 | 75,006 | 0 | 4,985 | 6,667,487 |
| President and Chief Operating Officer | ||||||||
| David Kirske | 194,192 | 120,000 | 0 | 4,181,040 | 103,133 | 0 | 901 | 4,599,266 |
| Chief Financial Officer, Treasurer and Corporate Secretary | ||||||||
| Paula Ragan | 420,170 | 0 | 1,081,575 | 0 | 0 | 0 | 1,138,824 | 2,640,569 |
| Former President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Adam Craig | $6,705,205 | — | — | — |
| John Volpone | 6,667,487 | — | — | — |
| David Kirske | 4,599,266 | — | — | — |
| Paula Ragan | 2,640,569 | 2,145,041 | — | +495,528 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adam Craig | Option | 529,201 | 3.14 | — |
| Adam Craig | Option | 2,329,154 | 1.42 | — |
| Adam Craig | Option | 1,609,873 | 1.42 | — |
| John Volpone | Option | 1,609,873 | 1.42 | — |
| John Volpone | Option | 2,329,154 | 1.42 | — |
| John Volpone | Option | 529,201 | 3.14 | — |
| David Kirske | Option | 352,800 | 3.14 | — |
| David Kirske | Option | 1,552,769 | 1.42 | — |
| David Kirske | Option | 1,073,249 | 1.42 | — |
The Company's compensation program is intended to reward NEOs for individual and Company-wide performance, align the interests of NEOs with those of stockholders, and motivate them to make important contributions to performance. Base salary is established based on role, responsibilities, skills, and experience, while annual bonuses are discretionary and based on performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | X4 Pharmaceuticals | 2025 | Paula Ragan | $420,170 | $1,081,575 | $0 | $0 | $2,640,569 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Adam Craig | DEF 14A | 2026-03-20 | 0001501697-26-000031 | Section “Summary Compensation Table” · page 30. As printed: 6,705,205. Filing ↗machine: span 515755–515764 |
| 2 | Section 01, John Volpone | DEF 14A | 2026-03-20 | 0001501697-26-000031 | Section “Summary Compensation Table” · page 30. As printed: 6,667,487. Filing ↗machine: span 530823–530832 |
| 3 | Section 01, David Kirske | DEF 14A | 2026-03-20 | 0001501697-26-000031 | Section “Summary Compensation Table” · page 30. As printed: 4,599,266. Filing ↗machine: span 537527–537536 |
| 4 | Section 01, Paula Ragan | DEF 14A | 2026-03-20 | 0001501697-26-000031 | Section “Summary Compensation Table” · page 30. As printed: 2,640,569. Filing ↗machine: span 520865–520874 |
| 5 | Section 07, pay ratio | 10-K | 2026-03-17 | 0001501697-26-000018 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 6 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 7 | X4 Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-03-20 | 0001501697-26-000031 | CEO total compensation as printed in X4 Pharmaceuticals's own proxy. As printed: 2,640,569. Filing ↗machine: span 520865–520874 |